Zotarolimus for the treatment of coronary artery disease: Pathophysiology, DES design, clinical evaluation and future perspective

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 6, 2009, Pages 1047-1058

  Brugaletta, Salvatore ^a   Burzotta, Francesco ^b   Sabaté, Manel ^a  

^a HOSPITAL SANT PAU   (Spain)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

BMS; Clinical trials; DES; Zotarolimus

Indexed keywords

'TAXUS'; ANTITHROMBOCYTIC AGENT; BIOLINX; BIOMATRIX; CYPHER; ENDEAVOR; EVEROLIMUS; NOBORL; PACLITAXEL; PIMECROLIMUS; PROMUS; RAPAMYCIN; RESOLUTE; TACROLIMUS; UNCLASSIFIED DRUG; XLENCE; ZOTAROLIMUS;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTERY INTIMA PROLIFERATION; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE ESCALATION; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTIMA; KIDNEY GRAFT REJECTION; NONHUMAN; PATHOPHYSIOLOGY; RESTENOSIS; REVIEW; SINGLE DRUG DOSE; STENT THROMBOSIS; TAXUS; THROMBOSIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FORECASTING; HUMANS; SIROLIMUS; TREATMENT OUTCOME;

EID: 67649631147     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902837998     Document Type: Review

References (60)

1. King III SB. Angioplasty from bench to bedside to bench. Circulation 1996;93:1621-1629 (Pubitemid 26131336)
2. Levine G, Chodos A, Loscalzo J. Restenosis following coronary angioplasty: clinical presentations and therapeutic options. Clin Cardiol 1995;18:693-703 (Pubitemid 26034662)
3. Edelman ER, Rogers C. Pathobiologic response to stenting. Am J Cardiol 1998;81:4E-6E
4. Lowe H, Oesterle S, Khachigian L. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002;39:183-193 (Pubitemid 34084620)
5. Goldberg S, De Gregorio J, Di Mario C, et al. Predictors of diffuse and aggressive intrastent restenosis. J Am Coll Cardiol 2001;37:1019-1025 (Pubitemid 32217600)
6. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323 (Pubitemid 37186209)
7. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780 (Pubitemid 34586912)
8. Grube E, Buellesfeld L. Initial experience with paclitaxel-coated stents. J Interv Cardiol 2002;15:471-476 (Pubitemid 35387387)
9. Stone GW, Ellis SG, Cox DA, et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231 (Pubitemid 38067635)
10. Pfisterer M, Brunner-La Rocca HP, Buser BT et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591 (Pubitemid 44881238)
11. Briguori C, Sarais C, Pagnotta P, et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol 2002;40:403-409 (Pubitemid 34833152)
12. Costa MA, Simon DL. Molecular basis of restenosis and drug-eluting stents. Circulation 2006;114:798-806
13. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977;55:48-51 (Pubitemid 8061941)
14. Caine RY, Collier DS, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989;2:227
15. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001;59:3-16 (Pubitemid 32055209)
16. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323 (Pubitemid 37186209)
17. Sabers CJ, Martin MM, Brun GJ, et al. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995;270:815-822
18. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Drug Dispos 2001;40:573-585 (Pubitemid 32758580)
19. Chen YW, Smith ML, Sheets M, et al. Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. J Cardiovasc Pharmacol 2007;49:228-235 (Pubitemid 46626015)
20. Buellesfeld L, Grube E. ABT578-eluting stent. The promising successor of sirolimus- and paclitaxel eluting stent concepts? Herz 2004;29:167-170
21. Crimack K, Xu X, Peykova D, et al. Physicochemical profiling of drug compound for the drug-eluting stents: ABT-578, rapamycin, paclitaxel and other drugs [abstract 501]. CRT 2005
22. Burke S, Kuntz RE, Schwartz LB. Zotarolimus (ABT-578) eluting stents. Adv Drug Deliv Rev 2006;58:437-446 (Pubitemid 43833332)
23. Nojima H, Tokunaga C, Eguchi S, et al. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 s6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 2003;278:15461-15464 (Pubitemid 36799651)
24. Wagner R, Mollison KW, Liu L, et al. Rapamycin analogs with reduced systemic exposure. Bioorg Med Chem Lett 2005;15:5340-5343 (Pubitemid 41463677)
25. Xue L, Sharma R, Cochran K, et al. The effect of the rapamycin derivative ABT-578 on canine smooth muscle cell and endothelial cell proliferation. Preclinical 2004;2:451-455
26. Schwartz RS, Burke SE, Cromack K, et al. Marked neointimal inhibition from a drug eluting stent: effects of local ABT-578 in the porcine coronary model [abstract]. Circulation 2002;106(Suppl II):448
27. Palaparthy R, Pradhan R, Chan J, et al. Pharmacokinetics and safety of ABT-578, a sirolimus (rapamycin) analog, after single intravenous bolus injection in healthy male volunteers. Clin Drug Invest 2005;25:491-498 (Pubitemid 41058448)
28. 52nd ASMS Conference, Nashville, TN; May 23-27, 2004
29. Sakurai R, Hongo Y, Ormiston J, et al. First human experience with the ABT-578 eluting phosphorylcholine polymer stent: a serial volumetric intravascular ultrasound analysis [abstract ACC]. 2004
30. Shrivastava S. A novel trilayered metal composite stent. Am J Cardiol 2004;94:158E
31. DuVall M, Ji Q, Clifford A, et al. ABT-578 elution profile and arterial penetration using the ZoMaxx drug-eluting stent [abstract]. Am J Cardiol 2004;94:223E
32. Abizaid A, Lansky AL, Fitzgerald PJ, et al. Percutaneous coronary revascularization using a trilayer phosphorylcholine-coated zotarolimus-eluting stent. Am J Cardiol 2007;99:1403-1411 (Pubitemid 46686636)
33. Lasave LI, Costa JDR Jr, Abizaid AA, et al. A three-dimensional intravascular ultrasound comparison between the new zotarolimus-eluting stent (ZoMaxx) and the non-drug eluted TriMaxx stent. J Invasive Cardiol 2007;19:303-308 (Pubitemid 47041850)
34. Chevalier B, Di Mario C, Neumann FJ, et al. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: the ZoMaxx I trial. J Am Coll Cardiol Intv 2008;5:524-532
35. Sketch M, Ball M, Rutherford B, et al. Evaluation of the Medtronic (Driver) cobalt-chromium allow coronary stent system. Am J Cardiol 2005;95:8-12 (Pubitemid 40051104)
36. Lewis AL, Stratfors PW. Phosphorylcholine-coated stents. J Long Term Eff Med Implants 2002;12:231-250 (Pubitemid 36232469)
37. Hayward JA, Chapman D. Biomembrane surface as models for polymer design: the potential for haemocompatibility. Biomaterials 1984;5:135-142 (Pubitemid 14116173)
38. Lewis AL, Tolhurst LA, Stratford PW. Analysis of a phosphorylcholine- based polymer coating on a coronary stent pre- and post- implantation. Biomaterials 2002;23:1697-1706 (Pubitemid 34158593)
39. Meredith IT, Ormiston J, Whitbourn R, et al. Four-year clinical follow-up after implantation of the Endeavor Zotarolimus-eluting Stent: ENDEAVOR I, the first-in-human study. Am J Cardiol 2007;100:56M-61M (Pubitemid 47576037)
40. Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806 (Pubitemid 44268230)
41. Kandzari DE, Leon MB, Popma JJ, et al. Comparison of Zotarolimus-eluting and sirolimus eluting stents in patients with native coronary artery disease. J Am Coll Cardiol 2006;48:2440-2447
42. Leon MB. Two-year follow-up from a prospective randomized trial comparing a Zotarolimus-eluting stent and a Paclitaxel-Eluting stent in patients with coronary artery disease. Oral presentation at TCT 08
43. Jain AK, Meredith IT, Lotan C, et al. Real-world safety and efficacy of the endeavour zotarolimus eluting stent: early data from the E-five registry. Am J Cardiol 2007;100:77M-83M; Rothman on behalf of the E-Five Investigators E-Five Registry primary endpoint results. Oral presentation at PCR 2008 (Pubitemid 47576040)
44. Gerhlick A, Kandzari DE, Leon MB, et al. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007;100:45M-55M
45. SORT-OUT III trial, orally presented by Jens Lassen at TCT 2008
46. Camezind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first generation drug-eluting stents: a cause for concern. Circulation 2007;115:1440-1455 (Pubitemid 46648381)
47. Rivero F, Moreno R, Barreales L, et al. Lower levels of in-stent late loss are not associated with the risk of stent thrombosis in patients receiving drug eluting stent. EuroInterv 2008;4:124-132
48. Biondi-Zoccai GGL, Agostoni P, Sheiban I. Last nail in the coffin of late lumen loss? EuroInterv 2008;4:31-32
49. Udipi K, Hezi-Yamit A, Chen M, et al. Development of a novel biocompatible polymer system for extended drug release in the next generation drug eluting stent. E-poster presented at the TCT 2006
50. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-1058 (Pubitemid 46328299)
51. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-342 (Pubitemid 352001347)
52. Carter A, Manlder RJ, Udipi K, et al. In vivo performance of a novel co-polymer system for extended release of zotarolimus in a next generation drug-eluting stent. TCT 2006
53. Meredith IT, Worthley S, Whitbourn R, et al. The next-generation Endeavor™ Resolute™ stent: 4-month clinical and angiographic results from the Endeavor™ Resolute™ first in man trial. Eurointerv 2007;3:50-53
54. Meredith IT, on behalf of the RESOLUTE I Investigators. The Medtronic Endeavor Resolute Polymer-based Zotarolimus-Eluting Stent Clinical Trial Program Update, TCT 2008
55. Serruys PW, de Jaegere P, Kimeneij F, et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495 (Pubitemid 24256751)
56. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-959 (Pubitemid 40342825)
57. Kim JW, Suh SY, Choi CU, et al. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus paclitaxel-eluting stent. J Am Coll Cardiol Intv 2008;1:65-71
58. Kim JW, Suh SY, Choi CU, et al. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus paclitaxel-eluting stent. J Am Coll Cardiol Intv 2008;1:65-71
59. Hamilos M, Ostojic M, Beleslin B, et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol 2008;51:2123-2129 (Pubitemid 351721001)
60. Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005;45:1574-1579 (Pubitemid 40704488)